Pfizer reports top-line results from two Lyrica® capsules CV phase 3b studies
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
List view / Grid view
News
GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
18 October 2013 | By GlaxoSmithKline
The application is based primarily on results from an international, multi-centre, randomised Phase III study of ofatumumab...
New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries
18 October 2013 | By Boehringer Ingelheim
"The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable..."
New study demonstrates importance of oral nutritional supplements in helping hospitals achieve medicare readmission reduction requirements
18 October 2013 | By Abbott
One in five Medicare patients is readmitted to a hospital each year at an estimated cost of $17.5 billion annually...
Pfizer receives european approval for label update regarding the use of Prevenar 13 in certain high-risk populations
17 October 2013 | By Pfizer
Label now includes information on use of Prevenar 13 in preterm infants, children and adolescents with sickle cell disease...
Merck presents new Pharmacokinetic data on ISENTRESS® (raltegravir) at 14th European AIDS conference
16 October 2013 | By Merck
Company confirms development program for investigational once daily (QD) dosing regimen of ISENTRESS...
Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction
16 October 2013 | By Sanofi
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
Novoeight® (turoctocog alfa) receives approval from the FDA
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
Gilead’s single tablet HIV Regimen Stribild® demonstrates durable viral suppression through three years of therapy
16 October 2013 | By Gilead
Long-term data in treatment-naïve patients highlight Stribild’s sustained efficacy, safety and tolerability profile...
Amgen announces appointment of Greg C. Garland to Board of Directors
16 October 2013 | By Amgen
Mr. Garland will serve on the Governance and Nominating Committee and the Audit Committee of the Board...
Janssen submits marketing authorisation application to European Medicines Agency
15 October 2013 | By Johnson & Johnson
...for a fixed-dose combination tablet of HIV-1 medicine Darunavir with Cobicistat...
AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
Lundbeck research projects secure funding from The Michael J. Fox Foundation
14 October 2013 | By H. Lundbeck A/S
The Michael J. Fox Foundation has donated 5.5 million kroner to two Danish research projects in Parkinson's disease...
